Echo Street Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Echo Street Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,183	Closed	-$368K	–	573
2023 Q1	$368K	Sell	9,183 -2,154	-19%	-$92.4K	﹤0.01%	336
2022 Q4	$525K	Sell	11,337 -4,371	-28%	-$172K	0.01%	272
2022 Q3	$650K	Buy	+15,708	New	+$807K	0.01%	224
2022 Q2	–	Sell	-3,219	Closed	-$234K	–	683
2022 Q1	$234K	Buy	+3,219	New	+$224K	﹤0.01%	545
2021 Q4	–	Sell	-4,634	Closed	-$418K	–	732
2021 Q3	$418K	Sell	4,634 -6,773	-59%	-$612K	﹤0.01%	462
2021 Q2	$1.09M	Buy	11,407 +5,170	+83%	+$539K	0.01%	197
2021 Q1	$710K	Buy	+6,237	New	+$849K	0.01%	228

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Echo Street Capital Management's RARE Position: Q2 2023 in Review

Echo Street Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 9,183 shares — an estimated $368K sold.

Echo Street Capital Management first reported a position in RARE in Q1 2021 and held it in 7 quarters. The position peaked at $1.09M in Q2 2021. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

Echo Street Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Echo Street Capital Management sold 9,183 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $368K.
Echo Street Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 7 quarters.
Echo Street Capital Management's Ultragenyx Pharmaceutical position peaked at $1.09M in Q2 2021.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Echo Street Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.